NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $2.39 -0.02 (-0.83%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.42 +0.02 (+1.05%) As of 08/8/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiff Oncology Stock (NASDAQ:CRDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$2.35▼$2.4450-Day Range$2.37▼$4.4552-Week Range$2.09▼$5.64Volume1.23 million shsAverage Volume3.19 million shsMarket Capitalization$159.01 millionP/E RatioN/ADividend YieldN/APrice Target$10.10Consensus RatingModerate Buy Company Overview Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Read More Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 39% of companies evaluated by MarketBeat, and ranked 680th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCardiff Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCardiff Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.41% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 2.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.41% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 2.83%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment0.74 News SentimentCardiff Oncology has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Cardiff Oncology this week, compared to 2 articles on an average week.Search Interest10 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $710,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Stock News HeadlinesGary W. Pace Buys 15,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) StockAugust 1, 2025 | insidertrades.comQ3 EPS Forecast for Cardiff Oncology Decreased by Analyst1 hour ago | americanbankingnews.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)Cardiff Oncology (NASDAQ:CRDF) Price Target Lowered to $10.00 at HC WainwrightAugust 8 at 2:18 AM | americanbankingnews.comCardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.70 Average Price Target from AnalystsAugust 5, 2025 | americanbankingnews.comWilliam Blair Boosts Earnings Estimates for Cardiff OncologyAugust 3, 2025 | americanbankingnews.comCardiff Oncology Insiders Land Bargain With Gains Of US$244kJuly 31, 2025 | finance.yahoo.comCardiff Oncology Reports Second Quarter 2025 Results and Provides Business UpdateJuly 31, 2025 | finance.yahoo.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $4.34 at the start of the year. Since then, CRDF shares have decreased by 44.9% and is now trading at $2.39. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) issued its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Cardiff Oncology had a negative net margin of 9,344.14% and a negative trailing twelve-month return on equity of 77.94%. Who are Cardiff Oncology's major shareholders? Top institutional investors of Cardiff Oncology include Blair William & Co. IL (3.79%), Geode Capital Management LLC (2.25%), Simplex Trading LLC and Creative Planning (0.05%). Insiders that own company stock include Gary W Pace, Lale White, James E Levine and Mark Erlander. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings7/29/2025Today8/08/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees20Year Founded1999Price Target and Rating Average Price Target for Cardiff Oncology$10.10 High Price Target$19.00 Low Price Target$3.50 Potential Upside/Downside+322.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.43 million Net Margins-9,344.14% Pretax Margin-9,344.14% Return on Equity-77.94% Return on Assets-63.65% Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio4.42 Sales & Book Value Annual Sales$680 thousand Price / Sales233.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book2.72Miscellaneous Outstanding Shares66,530,000Free Float61,403,000Market Cap$159.01 million OptionableOptionable Beta1.54 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:CRDF) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.